Shares of Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report) shot up 2.4% on Friday . The company traded as high as $3.42 and last traded at $3.38. 23,741 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 286,469 shares. The stock had previously closed at $3.30.
Pasithea Therapeutics Stock Up 2.4 %
The company has a 50 day simple moving average of $4.25 and a 200-day simple moving average of $5.08.
Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($3.71) earnings per share (EPS) for the quarter.
Pasithea Therapeutics Company Profile
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.
Recommended Stories
- Five stocks we like better than Pasithea Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- How to Invest in the Best Canadian Stocks
- Top-Performing Non-Leveraged ETFs This Year
- Learn Technical Analysis Skills to Master the Stock Market
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
